Clear cell renal cell carcinoma (ccRCC) is one of the most common malignant carcinomas and its molecular mechanisms remain unclear. Long noncoding RNA (lncRNA) could bind sites of miRNA which affect the expression of mRNA according to the competing endogenous (ceRNA) theory. The aim of the present study was to construct a ceRNA network and to identify key lncRNA to predict survival prognosis. We identified differentially expressed mRNA, lncRNA and miRNA between tumor tissues and normal tissues from The Cancer Genome Atlas database.
| INTRODUCTION
Renal cancer is one of the most common malignant cancers. 1 Despite the continuous progress in medical treatment, the incidence of the disease has increased year by year. 2 There are many types of renal cancer according to histopathologic and cell features. Among them, clear cell renal cell carcinoma (ccRCC) is the most common type. 3 The main and most effective treatment for ccRCC is radical nephrectomy. However, 30% of patients experience recurrence and advanced stage reduces the likelihood of survival. 4 Moreover, regional or distant metastases leads to a high rate of death. 5 Furthermore, ccRCC is resistant to chemotherapy and radiation therapy, so there is an urgent need to better understand the molecular mechanisms of the disease to find a new target for treatment.
Long noncoding RNA (lncRNA) are a subtype of non-coding RNA (ncRNA) with no protein-coding function. LncRNA are 200 nucleotides to 100 kb in length and regulate the expression of target genes transcriptionally and post-transcriptionally. 6 The expression of lncRNA is different in tumors compared with normal tissues and plays a key role in the development of cancers. 7 Furthermore, lncRNA could be used as early diagnosis and prognosis cancer biomarkers due to their stronger tissue specificity. 8 For example, in lung adenocarcinoma, lncRNA could be biomarkers for diagnosis and prognosis. 9 MicroRNA (miRNA) are a class of small, single-stranded, endogenous non-coding RNA consisting of [19] [20] [21] [22] [23] [24] [25] nucleotides that interact with the 3′-untranslated region of the mRNA of target genes to promote mRNA degradation and/or inhibit protein translation. 10, 11 Abnormal expression of miRNA can regulate the biological process by activating or inhibiting oncogenic genes, tumor suppressor genes or target proteins. 12, 13 Several recently published studies report that lncRNA can have the effect of sponging miRNA, which weakens the impact of miRNA on mRNA according to the theories about RNA regulation by competitive endogenous RNA (ceRNA). 14, 15 The primary theory is that RNA could interact with miRNA response elements (MRE). 16 Then, different genes compete for the identical miRNA, which forms a complex network of RNA regulation, thus affecting pathway and function. 17 In a study of hepatocellular cell carcinoma, Zhang explored lncRNA profiles and constructed an lncRNA-miRNA-mRNA network. 18 In addition, Xue et al constructed a ceRNA network of esophageal cancer. 19 In papillary renal cell carcinoma, a ceRNA network was also constructed. 20 However, studies of large-scale samples and microarray detection in ccRCC are still rare and the relationship between lncRNA and prognosis is unclear and urgently needs to be defined. Therefore, the construction of a ceRNA network has an important role in therapeutic decisions, prognosis prediction and therapeutic targeting to improve the overall survival of ccRCC patients.
In the present study, we obtained the lncRNA, miRNA and mRNA expression profiles of ccRCC normal tissue and tumor tissue from The Cancer Genome Atlas (TCGA). Furthermore, an lncRNAmiRNA-mRNA ceRNA network was constructed for ccRCC through integrated analysis, which can help in finding new targets and pathways to improve survival for patients. Finally, we put significant lncRNA into a prognosis analysis and found biomarkers to predict survival in ccRCC. between cancer tissues and normal tissues. 22 The genes that were not registered in GENCODE were abandoned to maximize data 
| MATERIALS AND METHODS

| Data collection
F I G U R E 1
| Function and pathway enrichment
To better understand the underlying function of aberrantly expressed genes, the gene ontology (GO) was needed. Therefore, we used the Database for Annotation Visualization and Integrated 
| Identification and selection of prognosisrelated lncRNA in the training set
All 519 patients were randomly grouped into a training set (n = 259) and a testing set (n = 260; as shown in Table 1 ). We used the univariate Cox proportional hazards regression to explore the differentially expressed lncRNA and estimated the expression of lncRNA with overall survival (OS) by R with the survival package. Then, we identified some lncRNA whose expression is significantly correlated with OS in univariate Cox proportional hazards regression analysis, which were used for multivariate analysis. We calculated the prognostic risk score as exp lncRNA1 * β lncRNA1 + exp lncRNA2 * β lncRNA2 + exp lncRNAn * β lncRNAn (exp, expression level, β, the regression coefficient derived from the multivariate Cox regression model). 26 The median risk score was 1.087797. All the patients were divided into low-risk and high-risk groups based on the median risk score. KaplanMeier survival curves were further used to calculate the OS of the different risk groups. A time-dependent receiver operating characteristic (ROC) curve analysis with 5 years as the defining point was performed with the R package "survival-ROC" to evaluate the predictive value of the risk score. The prognostic lncRNA in the training set were further explored in the testing and entire dataset. Patients were also divided into highrisk and low-risk groups according to the risk score. The ROC curve and survival were analyzed in the 2 datasets.
| The prognostic factors of clinical features
We carried out the univariate Cox regression analysis between clinical features (age, gender, race, neoadjuvant treatment, the histologic F I G U R E 5 Signifcant pathway enrichment of DEmRNA. Red represents the upregulated DEmRNA. Green represents the downregulated DEmRNA. Blue represents signaling pathway. DEmRNA, differentially expressed mRNA
The results showed the patients with high expression of COL4A4, ERMP1 and PRELID2 had a better overall survival (OS) (P < .05). In contrast, patients with low expression of NOG, SPI1, TGFβ1, TYRP1 and VIM had better overall survival (P < .05). ( ) Low expression; ( ) High expression.
grade, the pathologic stage and the risk) and OS using SPSS 22.0 software. The significant value was further explored in the multivariate Cox regression analysis.
| Statistical analysis
An unpaired t test was used to identify differentially expressed genes between tumor tissues and normal tissues. To further identify the gene associated-competing endogenous RNA, we combined the clinical data of ccRCC patients. The survival package in R was used to plot the survival curves.
3 | RESULTS
| Clinical characteristics of clear cell renal cell carcinoma patients
There were 519 tumor patients enrolled in the study. F I G U R E 7 Identification and performance evaluation of the 9-lncRNA signature in the training dataset. A, Kaplan-Meier survival curve analysis for overall survival of clear cell renal cell carcinoma patients using the 9-lncRNA signature in the training dataset; B, ROC curve analysis of the 9-lncRNA signature in the training dataset; C, The distributions of the RSlncRNA, survival status and expression profiles of the 9 lncRNA of patients in the training dataset and 74 (14.3%), respectively. A total of 17 patients underwent neoadjuvant therapy; the others did not. In addition, the number of tumors of TNM stage I, II, III and IV were 263 (50.7%), 55 (10.6%), 119 (22.9%) and 82 (15.8%), respectively. All the patients were randomly divided into the training set and the testing set.
There was no correlation between the 2 groups (P > .05). The results are listed in Table 1 . suggested that the expression of these genes can distinguish ccRCC from normal tissues.
| Competitive endogenous RNA network in clear cell renal cell carcinoma
Next, the potential interactions among the above genes were predicted according to the ceRNA hypothesis. A total of 89 DElncRNA were predicted to interact with 10 DEmiRNA by miRcode online tools (Table S1 ). Furthermore, we combined miRDB, TargetScan and miRanda to predict the candidate mRNA targets of DEmiRNA (Table 2 ). The 22 target DEmRNA that were also involved in the 2331 differential mRNA were enrolled in the ceRNA network (Figure 2) . In total, there were 89 DElncRNA, 10 DEmiRNA and 22
DEmRNA in the ceRNA network. Furthermore, Cytoscape software was used to construct the interactions among DElncRNA, DEmiRNA and DEmRNA (Figure 3 ).
| DEmRNA in the competitive endogenous RNA network
The functions and KEGG pathways of 22 DEmRNA in the ceRNA network were analyzed with DAVID and KOBAS. The results showed 4 GO terms (P < .01) and 13 KEGG pathways (corrected Pvalue < .05). The results of GO terms are shown in Table 3 and
Evaluation of the 9-lncRNA signature in the testing dataset. A, Kaplan-Meier survival curve analysis for overall survival of clear cell renal cell carcinoma patients using the 9-lncRNA signature in the testing dataset; B, receiver operating characteristic curve analysis of the 9-lncRNA signature in the testing dataset; C, the distributions of the RSlncRNA, survival status and expression profiles of the 9 lncRNA of patients in the testing dataset Table 4 .
Furthermore, we imported the above data into Cytoscape to calculate the characteristics of the network ( Figure 5 ). Next, the relationship between the 22 DEmRNA and OS was also explored. The results showed that patients with high expression of COL4A4, ERMP1 and PRELID2 had a better OS (P < .05). In addition, patients with low expression of NOG, SPI1, TGFβ1, TYRP1 and VIM had better OS (P < .05; Figure 6 ).
| DElncRNA in relation to overall survival in the training set
To further analyze the function of DElncRNA, we calculated the relationship between the 89 DElncRNA in the network and overall sur- Next, we calculated the 9 lncRNA expression-based survival risk score of the 259 patients. The median risk score was 1.087797. All the patients were divided into low-risk and high-risk groups based on the median risk score. The survival of 2 different groups was calculated using Kaplan-Meier curves, and the results showed that the risk was closed correlated with OS. Patients with high-risk scores had poorer OS than patients with low-risk scores (P < .001; Figure 7A ). The 5-year OS of the low-risk and high-risk groups were 86.7 (95%CI = .798-.943) and 42.9 (95%CI = .3377-.546), respectively. Furthermore, we evaluated the 9-lncRNA signature using the area under ROC curve (AUC) of the ROC curve. The result showed that the value of AUC was .786 ( Figure 7B ). The distributions of the F I G U R E 9 Evaluation of the 9-lncRNA signature in the entire dataset. A, Kaplan-Meier survival curve analysis for overall survival of clear cell renal cell carcinoma patients using the 9-lncRNA signature in the entire dataset; B, receiver operating characteristic curve analysis of the 9-lncRNA signature in the entire dataset; C, the distributions of the RSlncRNA, survival status and expression profiles of the 9 lncRNA of patients in the entire dataset risk score, survival state and expression of 9 lncRNA in the training set are shown in Figure 7C .
3.6 | The 9-lncRNA signature for survival prediction in the testing and the entire set Next, to further evaluate the 9-lncRNA signature for survival prediction in ccRCC patients, we tested it in the testing and entire sets.
The predictive model and cut-off point used were the same as for the training set. The testing set was divided into a low-risk group (n = 131) and a high-risk group (n = 129). The survival of the 2 risk groups was calculated by Kaplan-Meier survival curves as in the training set. Patients with high-risk scores had poorer OS than patients with low-risk scores (P < .001, Figure 8A ). The 5-year OS of the lowrisk and high-risk groups were 82.1 (95%CI = .747-.902) and 45.9
(95%CI = .369-.57), respectively. The AUC in the ROC curve was .722 ( Figure 8B ). The distributions of the risk score, survival state and expression of 9 lncRNA in the testing set are shown in Figure 8C .
The results for the entire set were similar. The patients with high-risk scores had poorer OS than patients with low-risk scores (P < .001; Figure 9A ). The 5-year OS of the low-risk and high-risk groups were 83.3 (95%CI = .779-.89) and 48 (95%CI = .415-.555),
respectively. The AUC in the ROC curve was .74 ( Figure 9B ). The distributions of the risk score, survival state and expression of 9 lncRNA in the entire set are shown in Figure 9C .
| The prognostic factors of clinical features
The clinical factors of 519 ccRCC patients were further evaluated using SPSS 22 software. The univariate Cox regression analysis showed that age, neoadjuvant treatment, histologic grade, pathologic stage and risk were factors affecting survival. However, in the multivariate COX regression analysis, age, histologic grade, pathologic stage and risk were independent prognostic indictors in ccRCC (Table 6 ). The survival curves were drawn using the Kaplan-Meier method, and the factors age, histologic grade, pathologic stage and risk were associated with OS (P = .001, <.001, <.001 and <.001; Figure 10 ). Furthermore, age, histologic grade and pathologic stage were also significant risk factors affecting survival. Therefore, we undertook a stratification analysis to further explore the signature of the 9 lncRNA within the same clinical factor.
First, we placed all 519 patients into a younger group (age < 62; n = 277) or an older group (age > 62; n = 242). The log-rank test result showed that the low-risk patients (n = 136) had a better OS than high-risk (n = 141) patients in the younger group (P < .001).
The result in the older group was similar ( Figure 11A) . The low-risk | 3345 patients (n = 111) had a better OS than the high-risk patients (n = 131; P < .001). Then, the patients were divided into an early stage (I + II; n = 315) group and a late-stage (III + IV) group. In the early stage group, the low-risk patients (n = 184) had a better OS than the high-risk patients (n = 131; P < .001). In the late-stage group, the result was similar (P < .001; Figure 11B ). Finally, we placed patients into a low-grade group (n = 239) or a high-grade group (n = 280). In the low-grade group, the low-risk patients (n = 141) had a better OS than the high-risk patients (n = 98; P < .001). In the high-grade group, the result was similar (P < .001; Figure 11C ).
| DISCUSSION
Renal cell carcinoma is one of the most common malignant carcinomas in the world and has a high incidence and mortality rate. 28 In a previous study, we identified biomarkers of papillary renal cell carcinoma associated with pathological stage by weighted gene coexpression network analysis. 29 CcRCC is the most common type of renal cancer, and there is an urgent need to explore the mechanism of the disease. LncRNA play important roles in tumor progression and may be biomarkers for clinical diagnosis and prognosis according to recent studies. For example, in colorectal cancer, the lncRNA AB073614 induced epithelial mesenchymal transition. 30 In cervical cancer, lncRNA SNHG20 promoted cell proliferation and invasion. 31 Furthermore, lncRNA were able to compete with mRNA for the binding sites of miRNA which affect the expression of mRNA through MRE. For example, the lncRNA UICLM acted as a ceRNA for miR-215 to regulate ZEB2 expression in colorectal cancer. 32 In gastric cancer, the lncRNA BC0032469 upregulated hTERT expression by sponging miR-1207, which promoted proliferation. 33 In hepatocellular cancer, the lncRNA SNHG6-003 also functions as a ceRNA to promote tumor progression. 34 Therefore, constructing a ceRNA network is important to explore the mechanism of the disease.
There are many studies on ceRNA networks in numerous cancers; however, few of them are on ccRCC. In addition, the sample sizes have not been large enough. Therefore, in the pre- LncRNA played a vital role in cancer and could be used to predict the survival prognosis. The lncRNA FMO6P and PRR26 were identified to construct a risk score to predict the prognostic value in lung cancer. 35 In pancreatic ductal adenocarcinoma, a 5-lncRNA signature (C9orf139, MIR600HG, RP5-965G21.4, RP11-436K8.1
and CTC-327F10.4) could be used to make prognoses for patients. 36 In ER-positive breast cancer, a 6-lncRNA (HAGLR, STK4-AS1, DLEU7-AS1, LINC00957, LINC01614 and ITPR1-AS1) signature was a potential prognostic marker for survival prediction. 37 In esophageal squamous cell cancer, a 3-lncRNA signature could predict overall survival. 38 In our study, we explored the correlation between survival and 89 DElncRNA in the training dataset. analysis proved that the 9-lncRNA signature was an independent prognostic factor to predict survival in ccRCC patients. Specifically, to our knowledge, this is the first study combining a ceRNA network constructed by TCGA databases and constructing an lncRNA risk score in ccRCC.
However, there are several limitations to our study. The main method in our study was bioinformatics technology, which appears as a promising tool to understand the function of gene and protein interactions, pathways and networks. However, the functions and networks of lncRNA are complex. In our study, the network was constructed only by means of the ceRNA theory. Moreover, a longer follow-up is needed to validate our findings. Finally, other databases still need to be used to verify the findings.
In conclusion, our study performed a comprehensive analysis of mRNA, miRNA and lncRNA expression profiles and clinical data of ccRCC patients in the TCGA database. We constructed a ceRNA network and identified a 9-lncRNA signature that is closely F I G U R E 1 1 Kaplan-Meier survival curve analysis for overall survival of patients stratified by age, stage and grade using the 9-lncRNA signature in the entire dataset. A, Kaplan-Meier survival curves of the younger patients group; B, KaplanMeier survival curves of the older patient group; C, Kaplan-Meier survival curves of the early stage patients group; D, KaplanMeier survival curves of the late-stage patients group; E, Kaplan-Meier survival curves of the low-grade patients group; F, Kaplan-Meier survival curves of the highgrade patients group YIN ET AL.
| 3347 associated with overall survival to predict prognosis. The 9 lncRNA were further proved to predict the survival risk in the testing and entire sets. Furthermore, multivariate analysis proved the 9-lncRNA signature to be an independent factor affecting survival and other clinical factors. Therefore, the current study not only provided the ceRNA molecular mechanisms, but also explored the potential of a novel 9-lncRNA signature as a candidate biomarker for ccRCC patients.
ACKNOWLEDGMENTS
We are grateful for free access to the TCGA databases.
CONF LICT OF I NTEREST
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
O R C I D
Hang Yin
http://orcid.org/0000-0002-0260-9130
